Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II, Open Label, Multicenter Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

Trial Profile

A Phase Ib/II, Open Label, Multicenter Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lacnotuzumab (Primary) ; Spartalizumab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Endometrial cancer; Malignant melanoma; Pancreatic cancer; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis; Novartis Pharma; Novartis Pharmaceuticals
  • Most Recent Events

    • 12 Jul 2021 Number of treatment arms have been increased from 4 to 11 by the addition of 4 new phase-2 arms and 2 new phase-1b arms. the previously existing arms have also been labelled as phase-1 b arms. Additionally, 9 new primary end-points have been added.
    • 21 May 2021 Results presented at the 112th Annual Meeting of the American Association for Cancer Research
    • 09 Jul 2020 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top